Abstract
Atrial fibrillation (AF) is a common arrhthymia that exists in both the acute and chronic form. As the molecular basis of arrhythmogenesis is further elucidated, the discovery of novel antiarrhythmic agents, which can be tailored to individual patients and the particular subtype of AF, while minimizing potential side effects, will become possible.
| Original language | English |
|---|---|
| Pages (from-to) | 84-88 |
| Number of pages | 5 |
| Journal | Current Opinion in Investigational Drugs |
| Volume | 3 |
| Publication status | Published - 1 Jan 2001 |